Significant progress in the field of gene therapy means it’s important to determine methods that can be tailored to remove and/or inactivate any potential viral contaminant(s) in the production process. In the final installment of our four-part Webinar Series: Platforms for Gene Therapy Characterization, this webinar focuses on the challenges associated with performing viral clearance (VC) studies on viral vector products. We will also discuss a database of VC studies generated specifically for gene therapy products.
Tareq Jaber, PhD
Manager Process Evaluation
Amanda Budzilowicz, MS, Charles River
Process Evaluation Research Associate
View the other webinars in this series:
- Analytical Ultracentrifugation for Characterization of AAV Gene Delivery Vectors (On Demand)
- A Platform Approach for Analytical Methods to Support Adeno-Associated Virus (AAV) Gene Therapy Products (On Demand)
- Advanced Mass Spectrometry-based Characterization of Adeno-Associated Viruses and Next Generation Biologics (On Demand)
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.